Changes in Hong Kong stocks | Insili Intelligence (03696) rose more than 5%, and the chairman of the board plans to increase its shareholding, Citi indicates that the company's proprietary platform can create exponential value

The Zhitong Finance App learned that Insili Intelligence (03696) rose by more than 5%. As of press release, it had risen 4.98% to HK$49.34, with a turnover of HK$580 million.

According to the news, on September 4, Insilicon Intelligence issued an announcement. Based on confidence in the company's future development prospects and recognition of the company's long-term investment value, Aleksandrs Zavoronkovs, Chairman of the Board of Directors, Executive Director, CEO and Chief Commercial Officer, initiated a plan to purchase additional shares of the company on the open market with personal funds on the premise of complying with the “Hong Kong Stock Exchange Limited Securities Listing Rules” and other applicable laws and regulations. The share purchases will be carried out within September 2026, with an estimated total value of up to HK$16 million. Previously, Mr. Zavoronkovs also invested in the company's Series D financing in 2022.

According to a research report released by Citigroup, market research agency data shows that the global pharmaceutical R&D investment in 2026 is estimated at about US$313 billion, and the AIDD penetration rate is only about 6%. Citi believes that there is huge room for market growth and predicts that the global AI drug discovery ecosystem will reach about 50 billion US dollars by 2030, mainly in the three major areas of data generation, wet laboratory verification, and AI native discovery. The bank believes that as a hybrid enterprise with both platforms and pipelines, its AIDD proprietary platform can continuously generate “higher quality and differentiated” clinical assets, which can create exponential value.